These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16984942)

  • 1. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.
    Russell AS; Wallenstein GV; Li T; Martin MC; Maclean R; Blaisdell B; Gajria K; Cole JC; Becker JC; Emery P
    Ann Rheum Dis; 2007 Feb; 66(2):189-94. PubMed ID: 16984942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
    Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
    J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
    Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
    Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial.
    Li T; Gignac M; Wells G; Shen S; Westhovens R
    Clin Ther; 2008 Apr; 30(4):734-48. PubMed ID: 18498922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
    Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK
    Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
    Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
    Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
    Takeuchi T; Matsubara T; Nitobe T; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2013 Mar; 23(2):226-35. PubMed ID: 22684431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechiński J; Li T; Teng J; Becker JC; Westhovens R
    Arthritis Rheum; 2008 Apr; 58(4):953-63. PubMed ID: 18383390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
    Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
    Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
    Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
    Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept.
    Li T; Wells G; Westhovens R; Emery P; Becker JC; Tugwell P
    Value Health; 2011; 14(2):361-70. PubMed ID: 21296603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.
    Kremer JM; Peterfy C; Russell AS; Emery P; Abud-Mendoza C; Sibilia J; Becker JC; Westhovens R; Genant HK
    J Rheumatol; 2014 Jun; 41(6):1077-87. PubMed ID: 24786925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.